Drug Design Targeting ProRS in Anaerobic Parasites

针对厌氧寄生虫中 ProRS 的药物设计

基本信息

  • 批准号:
    9091419
  • 负责人:
  • 金额:
    $ 25.53万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2015
  • 资助国家:
    美国
  • 起止时间:
    2015-06-17 至 2018-05-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The universally essential enzyme prolyl-tRNA synthetase (ProRS) has recently been identified as a molecular target for the drug halofuginone, which is derived from natural products with anti-malarial activity. Halofuginone exhibits a conserved mode of binding to both plasmodium and human ProRS as shown by crystal structures of the respective drug:enzyme complexes. We have shown that halofuginone is also blocks growth and encystation of Giardia in culture with an EC50 approximately equal to that of the current front line anti-giardiasis drug metronidazole. Nevertheless the active site of ProRS from Giardia and from Trichomonas species differs significantly from that of the human and plasmodium homologs, as we have shown by sequence analysis and by determining a Giardia ProRS crystal structure. This strongly suggests that suitable modification of halofuginone will both increase its potency and its specificity of action against Giardia and Trichomonas parasites relative to the human host. We will evaluate such compounds for activity in suppressing parasite growth, cell attachment, or encystation. A primary goal is to use SAR-guided synthetic chemistry to develop compounds that are orally bioavailable, sufficiently potent, lack toxicity, and cure animal models of Giardia infection. By the end of this project we expect to have lead compounds for evaluation as new drugs against giardiasis and trichomoniasis.
 描述(由申请人提供):普遍必需的酶脯氨酰-tRNA合成酶(ProRS)最近被鉴定为药物常山酮的分子靶标,常山酮衍生自具有抗疟疾活性的天然产物。常山酮表现出与疟原虫和人ProRS结合的保守模式,如通过相应药物:酶复合物的晶体结构所示。我们已经表明,常山酮也可以阻断培养物中贾第虫的生长和包囊形成,其EC 50约等于当前一线抗贾第虫病药物甲硝唑的EC 50。然而,从贾第鞭毛虫和毛滴虫物种的ProRS的活性位点显着不同的人类和疟原虫同源物,我们已经通过序列分析和确定贾第鞭毛虫ProRS晶体结构。这强烈表明,常山酮的适当修饰将增加其相对于人类宿主对贾第虫和毛滴虫寄生虫的效力和作用特异性。我们将评估这些化合物在抑制寄生虫生长、细胞附着或包囊形成中的活性。主要目标是使用SAR指导的合成化学来开发口服生物可利用的、足够有效的、无毒的化合物,并治愈贾第虫感染的动物模型。在这个项目结束时,我们希望有先导化合物作为治疗贾第虫病和滴虫病的新药进行评价。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETHAN A MERRITT其他文献

ETHAN A MERRITT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETHAN A MERRITT', 18)}}的其他基金

Novel Therapeutics Targeting Giardia Kinases
针对贾第鞭毛虫激酶的新疗法
  • 批准号:
    9221721
  • 财政年份:
    2016
  • 资助金额:
    $ 25.53万
  • 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
  • 批准号:
    8362112
  • 财政年份:
    2011
  • 资助金额:
    $ 25.53万
  • 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
  • 批准号:
    8362415
  • 财政年份:
    2011
  • 资助金额:
    $ 25.53万
  • 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
  • 批准号:
    7937610
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
  • 批准号:
    8097594
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
  • 批准号:
    8288293
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
  • 批准号:
    8688133
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
Calcium Dependent Protein Kinase 1 as a drug target for T. gondii and C. parvum
钙依赖性蛋白激酶 1 作为弓形虫和微小弯曲菌的药物靶点
  • 批准号:
    8485534
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
MEDICAL STRUCTURAL GENOMICS OF PATHOGENIC PROTOZOA
致病原虫的医学结构基因组学
  • 批准号:
    8170019
  • 财政年份:
    2010
  • 资助金额:
    $ 25.53万
  • 项目类别:
Prediction of Protein Crystallization and Diffraction Quality
蛋白质结晶和衍射质量的预测
  • 批准号:
    7707893
  • 财政年份:
    2009
  • 资助金额:
    $ 25.53万
  • 项目类别:

相似海外基金

Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
  • 批准号:
    10591918
  • 财政年份:
    2023
  • 资助金额:
    $ 25.53万
  • 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
  • 批准号:
    23K15383
  • 财政年份:
    2023
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
  • 批准号:
    23H03556
  • 财政年份:
    2023
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
  • 批准号:
    23K17212
  • 财政年份:
    2023
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
  • 批准号:
    22H03519
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
  • 批准号:
    563657-2021
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10521849
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
  • 批准号:
    10671022
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
  • 批准号:
    10670918
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
  • 批准号:
    2706416
  • 财政年份:
    2022
  • 资助金额:
    $ 25.53万
  • 项目类别:
    Studentship
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了